PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Scope & Guideline

Advancing knowledge in pharmacology and public health.

Introduction

Welcome to your portal for understanding PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1053-8569
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1992 to 2024
AbbreviationPHARMACOEPIDEM DR S / Pharmacoepidemiol. Drug Saf.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'Pharmacoepidemiology and Drug Safety' focuses on the study of the utilization and effects of drugs in large populations, emphasizing the importance of real-world evidence in understanding drug safety and effectiveness. This journal aims to disseminate research that enhances the understanding of drug-related issues in diverse populations, providing insights that can inform clinical practices and regulatory policies.
  1. Real-world evidence and drug utilization studies:
    The journal emphasizes studies that assess the use of medications in real-world settings, providing insights on prescribing patterns, adherence, and the effects of medications on various populations.
  2. Pharmacovigilance and safety monitoring:
    Research on adverse drug reactions and safety monitoring systems is a core focus, aiming to identify and mitigate risks associated with drug use.
  3. Comparative effectiveness research:
    The journal publishes studies comparing the effectiveness of different treatment options, including new therapies versus standard treatments, to inform clinical decision-making.
  4. Methodological advancements in pharmacoepidemiology:
    Papers often explore innovative methodologies for analyzing observational data, including statistical techniques for bias correction and causal inference.
  5. Impact of regulatory interventions:
    The journal frequently features studies evaluating the impact of regulatory changes on drug utilization and safety outcomes, providing critical insights for policymakers.
The journal is witnessing an evolution in its research focus, with several emerging themes gaining traction. These trends reflect the changing landscape of healthcare and the increasing complexity of pharmacotherapy.
  1. Real-world data integration:
    There is a growing emphasis on integrating real-world data from various sources, including electronic health records and claims data, to inform drug safety and effectiveness assessments.
  2. Machine learning and artificial intelligence applications:
    The application of machine learning techniques for predicting treatment outcomes and identifying adverse drug reactions is rapidly trending, showcasing the potential for advanced analytics in pharmacoepidemiology.
  3. Long COVID and its pharmacological implications:
    Research addressing the long-term effects of COVID-19 and the pharmacological treatment of associated symptoms is emerging as a significant theme, driven by the ongoing pandemic.
  4. Patient-centered outcomes and health-related quality of life:
    There is an increasing focus on studies that assess patient-reported outcomes and the impact of medications on quality of life, emphasizing the need for patient-centered approaches in treatment evaluations.
  5. Pharmacogenomics and personalized medicine:
    Research exploring the role of genetic factors in drug response and the tailoring of pharmacotherapy to individual genetic profiles is gaining momentum, reflecting advances in precision medicine.

Declining or Waning

While the journal has maintained a strong focus on various aspects of pharmacoepidemiology, certain themes appear to be declining in prominence based on recent publication trends. This section highlights these waning areas.
  1. Traditional randomized controlled trials (RCTs):
    There seems to be a shift away from traditional RCTs in favor of real-world studies, as researchers increasingly focus on how drugs perform in everyday clinical settings rather than in controlled trial environments.
  2. Basic pharmacokinetic studies:
    Research centered on basic pharmacokinetics is becoming less prominent, with a growing preference for studies that incorporate pharmacogenomics and personalized medicine approaches.
  3. Historical analyses of drug utilization:
    There is a noticeable decline in papers focused on historical drug utilization trends, as the emphasis shifts toward current practices and immediate implications for patient care.
  4. Single-drug studies:
    Studies focusing on the safety and efficacy of single drugs without considering multi-drug interactions or complex treatment regimens are decreasing, reflecting a broader understanding of polypharmacy in patient populations.

Similar Journals

European Journal of Hospital Pharmacy

Championing Excellence in Hospital Pharmaceutical Care
Publisher: BMJ PUBLISHING GROUPISSN: 2047-9956Frequency: 6 issues/year

The European Journal of Hospital Pharmacy, published by the prestigious BMJ PUBLISHING GROUP, stands as a vital resource in the field of pharmacy, specifically focused on practices within hospital settings. With its ISSN 2047-9956 and E-ISSN 2047-9964, this journal provides an essential platform for researchers, practitioners, and students to disseminate and access high-quality research that influences clinical practice. Recognized for its significant impact, the journal has achieved a commendable Q2 ranking in both the Pharmacology, Toxicology and Pharmaceutics (miscellaneous) and Pharmacy categories according to Scopus, highlighting its status within the academic community. The journal is indexed among the top 18% in its category, showcasing innovative research and advancements in the field. While the European Journal of Hospital Pharmacy does not operate under an open-access model, its deep commitment to enhancing pharmaceutical care within European hospital settings remains undeterred. The journal also covers a converged period from 2010 to 2024, providing comprehensive insights into evolving practices and challenges. As a premier publication, it plays an essential role in education and professional development, making it indispensable for those involved in pharmacy and healthcare.

JOURNAL OF CLINICAL PHARMACOLOGY

Transforming Clinical Practice with Cutting-Edge Research
Publisher: WILEYISSN: 0091-2700Frequency: 12 issues/year

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

CLINICAL DRUG INVESTIGATION

Advancing knowledge in clinical pharmacology.
Publisher: ADIS INT LTDISSN: 1173-2563Frequency: 12 issues/year

CLINICAL DRUG INVESTIGATION is a prestigious journal dedicated to the fields of Medicine and Pharmacology, published by ADIS INT LTD in the United Kingdom. With an ISSN of 1173-2563 and an E-ISSN of 1179-1918, this journal has been a crucial contributor to the scientific community since its inception in 1995. Recognized for its significant impact, it holds a commendable Q2 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, placing it firmly in the 70th percentile within its field. Researchers, professionals, and students alike benefit from its commitment to publishing innovative studies and comprehensive reviews that advance understanding and application of clinical drugs. Although it does not currently offer open access options, its rigorous peer-review process ensures the integrity and quality of published articles. The journal's scope encompasses a wide range of topics related to drug investigation, making it an essential resource for anyone involved in medical research and pharmacological practice.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Advancing pharmacological knowledge for better patient care.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Safety

Leading the way in safety research and knowledge sharing.
Publisher: MDPIISSN: Frequency: 4 issues/year

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

DRUGS IN R&D

Leading the charge in pharmacology and toxicology advancements.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

Drug Healthcare and Patient Safety

Transforming healthcare delivery with cutting-edge insights.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1365Frequency: 1 issue/year

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

Journal of Pharmaceutical Health Services Research

Advancing pharmaceutical knowledge for better health outcomes.
Publisher: OXFORD UNIV PRESSISSN: 1759-8885Frequency: 4 issues/year

Journal of Pharmaceutical Health Services Research, published by Oxford University Press, stands as a vital resource within the fields of pharmacology, toxicology, and health economics. With a focus on the integration of pharmaceutical science and healthcare services, this journal addresses the rapidly evolving challenges faced by researchers and practitioners alike, promoting innovative solutions that can enhance patient care and improve health outcomes. Its Q3 ranking in key categories such as Economics and Pharmacology further highlights its significance in the academic landscape. Although not an open-access journal, the Journal of Pharmaceutical Health Services Research provides a platform for high-quality research and comprehensive reviews, making it an essential reference for those dedicated to advancing knowledge and practice in pharmaceutical health services. With converged years from 2010 to 2024, the journal continues to contribute valuable insights that foster collaboration among academics, industry professionals, and policymakers, reinforcing its role as a cornerstone of pharmaceutical research and health service innovation.

Drugs-Real World Outcomes

Bridging research and practice for better health outcomes.
Publisher: SPRINGERNATUREISSN: 2199-1154Frequency: 4 issues/year

Drugs-Real World Outcomes, published by SPRINGERNATURE, is an influential open access journal dedicated to the dissemination of research concerning the real-world impact of pharmacological therapies. Since its inception in 2014, this journal has established a significant presence in the field of Pharmacology, evidenced by its classification in the Q2 quartile for 2023 and a Scopus rank of #141 out of 272 in the medical pharmacology category, placing it in the 48th percentile. The journal’s scope encompasses a diverse range of studies aimed at bridging the gap between clinical research and practical outcomes, making it an essential resource for researchers, healthcare professionals, and students alike. Located in Switzerland, Drugs-Real World Outcomes allows researchers unfettered access to vital data, enhancing knowledge translation and improving health care practices. As it continues to evolve, the journal remains committed to fostering high-quality research that informs and advances the field of pharmacological therapies.

JOURNAL OF PHARMACY TECHNOLOGY

Exploring the forefront of pharmacy technology and application.
Publisher: SAGE PUBLICATIONS INCISSN: 8755-1225Frequency: 6 issues/year

JOURNAL OF PHARMACY TECHNOLOGY is a premier publication in the field of Pharmaceutical Science, established in 1989 and published by SAGE PUBLICATIONS INC. This journal serves as an essential resource for professionals, researchers, and students dedicated to the advancements in pharmacy technology and the application of innovative solutions in pharmaceutical practices. With an ISSN of 8755-1225 and an E-ISSN of 1549-4810, the journal provides a rigorous peer-reviewed platform for disseminating cutting-edge research and case studies. As of 2023, it is ranked Q3 in the Scopus categories of Pharmacology, Toxicology, and Pharmaceutics, highlighting its relevance in the field. Although it currently does not offer an Open Access option, JOURNAL OF PHARMACY TECHNOLOGY aims to remain a critical avenue for scholarly communication and knowledge dissemination among practitioners in the pharmaceutical sector, ensuring they stay informed of the latest trends and findings that impact their work.